Inventiva SA Stock
€2.10
Your prediction
Inventiva SA Stock
Pros and Cons of Inventiva SA in the next few years
Pros
Cons
Performance of Inventiva SA vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Inventiva SA | 0.480% | 1.951% | 0.723% | -44.267% | -48.837% | -79.981% | - |
| Immunic Inc. | -2.980% | 14.369% | 11.498% | 1.925% | -3.706% | -82.947% | -89.056% |
| Actinium Pharmaceuticals Inc. | 1.370% | 5.214% | -6.477% | -72.984% | -62.942% | -71.121% | -71.872% |
| NanoViricides Inc. | -2.700% | -2.703% | -15.294% | 18.033% | 52.381% | -59.299% | -57.066% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Analyzing the financials of Inventiva, a company operating within the Biotechnology & Medical Research sector, reveals a complex picture marked by both challenges and opportunities. Despite its innovative potential in the biotech field, the financial statements showcase significant operational hurdles, ongoing losses, and issues surrounding liquidity and equity value. Such factors raise questions about the company's sustainability and future growth potential.
Strong Revenue Growth: Inventiva reported a quarterly revenue growth of 7.3%, which indicates that the company is making strides in expanding its market presence and sales channels. This upward trend in revenue is promising for a biotech firm as it suggests an increasing demand for its products or services.
Market Capitalization: With a market capitalization of approximately €117.29 million, Inventiva maintains a noteworthy position in the market. This valuation places the company on the radar of potential investors, especially those interested in biotech advancements.